HC Wainwright Reaffirms “Buy” Rating for Dyadic International (NASDAQ:DYAI)

HC Wainwright reissued their buy rating on shares of Dyadic International (NASDAQ:DYAI) in a research report released on Monday morning, Benzinga reports. The firm currently has a $6.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Dyadic International’s Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.11) EPS.

Dyadic International Stock Performance

NASDAQ:DYAI opened at $1.37 on Monday. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.29. The firm has a market capitalization of $40.06 million, a price-to-earnings ratio of -4.89 and a beta of 0.73. The firm’s fifty day simple moving average is $1.74 and its 200 day simple moving average is $1.60. Dyadic International has a twelve month low of $1.19 and a twelve month high of $2.67.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter. The company had revenue of $0.33 million for the quarter. Dyadic International had a negative return on equity of 116.14% and a negative net margin of 347.92%. During the same quarter in the previous year, the company posted ($0.03) EPS. As a group, equities research analysts expect that Dyadic International will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. Callan Capital LLC purchased a new position in Dyadic International, Inc. (NASDAQ:DYAI) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned about 0.09% of Dyadic International at the end of the most recent quarter. 27.95% of the stock is owned by institutional investors and hedge funds.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.